Insmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017
April 26 2017 - 7:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that it will release its first quarter 2017
financial results on Wednesday, May 3, 2017.
Will Lewis, president and chief executive officer, will host a
conference call for investors beginning at 8:30 a.m. ET on
Wednesday, May 3, 2017 to discuss the financial results and provide
a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (844) 707-0669 (domestic) or (703)
639-1223 (international) and referencing conference ID number
3999935. The call will also be webcast live on the internet on the
company's website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through May 17, 2017 by dialing
(855) 859-2056 (domestic) or (404) 537-3406 (international) and
referencing conference ID number 3999935. A webcast of the call
will also be archived for 90 days under the Investor Relations
section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE®
(liposomal amikacin for inhalation) for adult patients with
treatment refractory nontuberculous mycobacteria (NTM) lung disease
caused by Mycobacterium avium complex (MAC), a rare and often
chronic infection that is capable of causing irreversible lung
damage and can be fatal. There are currently no approved inhaled
products specifically indicated for the treatment of refractory NTM
lung infections caused by MAC in the United States or European
Union (EU). Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic
potential in non-CF bronchiectasis, and INS1009, an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare disorders, including
pulmonary arterial hypertension (PAH). For more information, visit
www.insmed.com.
"Insmed" and "ARIKAYCE" are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Investor Contact:
Laura Perry or Heather Savelle
Argot Partners
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Apr 2023 to Apr 2024